Esperion Therapeutics, Inc. - 8-K Filing
Esperion Therapeutics held its annual meeting on May 28, 2026, where stockholders approved an amendment to the company's 2022 Stock Option and Incentive Plan to increase the authorized shares by 7 million. The proposal passed with 108,150,213 votes in favor versus 22,489,001 against. Additionally, two Class I directors were elected: J. Martin Carroll (105,082,565 for) and Sheldon L. Koenig (109,672,941 for). (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Offi, 5.07 below, at the Annual Meeting, the Company’s stockholders approved an amendment (“Plan Amendment”) to the Esperion Therapeutics, Inc, 9.01 Financial Statements and Exhibits)
Tickers: $ESPR